Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. director Craig A. Johnson received a grant of stock options as part of his compensation. He was awarded 23,931 Director Stock Options, each giving the right to buy one common share at an exercise price of $15.67 per share.

The options vest one year from the grant date and expire on June 4, 2036. Following this grant, Johnson holds 23,931 options directly, with no open-market buying or selling reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Johnson Craig A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	23,931	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 23,931 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 23,931 options Exercise price: $15.67 per share Expiration date: June 4, 2036 +2 more

5 metrics

Option grant size 23,931 options Director stock option award to Craig A. Johnson

Exercise price $15.67 per share Exercise price for Director Stock Option grant

Expiration date June 4, 2036 Option term for director grant

Vesting schedule 1-year cliff vesting Options vest one year from date of grant

Post-grant holdings 23,931 options Total options held following transaction

Key Terms

Director Stock Option (right to buy), exercise price, expiration date, grant, award, or other acquisition, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "15.6700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest financial

"The options shall vest one year from date of grant."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Craig A

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$15.67	06/04/2026		A		23,931		(1)	06/04/2036	Common Shares	23,931	$0	23,931	D

Explanation of Responses:

1. The options shall vest one year from date of grant.

Remarks:

	/s/ Craig Johnson	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aurinia Pharmaceuticals (AUPH) report for Craig A. Johnson?

Aurinia Pharmaceuticals reported a compensation-related grant of 23,931 director stock options to Craig A. Johnson. These options provide the right to purchase common shares at a fixed exercise price and do not reflect any open-market buying or selling activity.

What is the exercise price of the new Aurinia (AUPH) director stock options?

The granted director stock options have an exercise price of $15.67 per common share. This means Johnson can buy Aurinia shares at $15.67 once the options vest, regardless of the market price at that time.

When do Craig A. Johnson’s Aurinia (AUPH) stock options vest and expire?

The director stock options granted to Craig A. Johnson vest one year from the date of grant. They carry an expiration date of June 4, 2036, after which any unexercised options will lapse and can no longer be used.

How many Aurinia (AUPH) options does Craig A. Johnson hold after this Form 4?

After this reported grant, Craig A. Johnson holds 23,931 stock options directly. All these options come from this single award, and the filing does not report any additional derivative positions remaining beyond this grant.

Does this Aurinia (AUPH) Form 4 show any insider share sales or purchases?

The Form 4 does not show any open-market purchases or sales of Aurinia common shares. It only reports a grant of director stock options, which is a non-cash, compensation-related acquisition rather than a market transaction.